BMS and Concerto HealthAI Agreement Accelerates Precision Oncology Innovations

Published on: 

Applied Clinical Trials

The multi-year strategic agreement between Bristol-Myers Squibb and Concerto HealthAI announced will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials for precision treatment and improved patient outcomes. 

Read the full release here.